Job offersmore »
- Managing Grower - Australia
- Senior Grower - Talbotville, Ontario, Canada
- Operations Manager - Fresh Produce
- Senior Account Manager Retail - Netherlands
- Supply Allocation and Inventory Manager - Fresh Produce, Italy
- Senior Grower - Katunga, Australia
- Key Account Manager - Netherlands
- Accountmanager aardappelinkoop België / Frankrijk
- International Retail Manager - Netherlands
- Quality Assurance Team EA Region -Antwerp- Quality Supervisor, Belgium
Top 5 - yesterday
Top 5 - last week
- "We are now the only people producing the tubers hydroponically"
- Oxygen level in water: an underestimated factor in plant growth
- Bitcoin mining powers tomato greenhouse
- How the rise of Amazon will urge you to create a brand in fresh produce
- UV light provides novel method to improve crop performance and yield
Top 5 - last month
Exchange ratesmore »
WeedMD, Technion-Israel Institute of Technology partner in MMJ researchWeedMD, a federally-licensed producer and distributor of medical cannabis, has joined the Cannabis Database Project led by the Technion-Israel Institute of Technology. Together, they will be collaborating in the research of cannabinoid and terpenoid profiles of 25 of WeedMD’s cannabis strains. This data will be added to an international database that correlates pharmacological effects used to determine the most effective cannabis treatments – strains, dose, and route of administration – for clinical purposes. This is just the first of multiple research and development initiatives WeedMD is embarking on, and plans to announce, as the company further develops its medical cannabis offering for both the domestic and global medical cannabis markets.
“We are proud to be at the forefront of investing in cannabis research, awareness and education. There are hundreds of cannabis strains available to medical patients, but each of these strains has a unique chemical profile, as well potentially unique medical properties. It’s inspiring to see that progressive thinkers are collating their data for leading-edge cannabis analysis,” said Dr. Luc Duchesne, Chief Scientific Officer at WeedMD. “A significant barrier to the standardization of medical cannabis is identifying strains that are effective in the treatment of specific medical conditions and Technion is making ground-breaking discoveries to this effect. While we pride ourselves as a science-focused organization, we are privileged to augment our research and development capabilities with the leader in medical cannabis research.”
“WeedMD is in a unique position to contribute data for our research studies and we’re proud to welcome them to our Cannabis Research Project. For starters, we’ve identified 25 of WeedMD’s strains that will undergo analysis for exact chemical compound composition pertaining to treatment of certain medical conditions,” said Dr. David Meiri, Head of the Laboratory of Cancer Biology and Cannabinoid Research at Technion-Israel Institute of Technology. “We recently hosted members of the WeedMD team in Israel for important discussions on knowledge transfer and we’re looking forward to this collaboration that could benefit Canadian, Israeli and worldwide medical cannabis patients for years to come.”
Cannabis Database Project & WeedMD’s involvement
The Cannabis Database Project aims to construct an integrated database with both clinical data on cannabis patients as well data on cannabis usage history for patients in Israel and abroad. Acquired data from growers, Health Maintenance Organizations (HMOs), and other sources will be used for statistical and computational analyses, aimed to identify patient-class specific treatments and organize them into an accessible website for patients and physicians.
WeedMD will contribute samples of 25 strains to state-of-the-art mass-spectrometry to consolidate into comprehensive profiles of the cannabinoid composition for a variety of cannabis strains that are used for clinical purposes in Israel. Technion has already profiled more than 150 strains, including all strains currently available under Israel’s regulated medical cannabis market. The patient-specific and cannabis strain databases are combined, analyzed, and used to derive optimized treatment options thereby maximizing disease specific therapeutic efficacy while minimizing side-effects. For each patient class, the project analyzes the risks of side effects associated with different cannabis treatments against the patients’ genetic backgrounds.
For more information:
250 Elm Street
Aylmer, ON. N5H 2M8
T: 1-844-WEEDMD-6 (1-844-933-3636)
F: 1-844-WEEDMD-7 (1-844-933-3637)
Publication date: 2/20/2018
Other news in this sector: